13 . 08 .2024
Press release
Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis
05 . 08 .2024
Press release
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
30 . 07 .2024
Press release
Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe
25 . 07 .2024
Press release
Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024
25 . 07 .2024
Press release
Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance
09 . 07 .2024
Press release
Galderma introduces high potency Cetaphil serums designed for sensitive skin
01 . 07 .2024
News story
Shaping the future: Gerry Muhle on the technologies driving dermatology
19 . 06 .2024
Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence
23 . 05 .2024
Press release
Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets